Omeprazol and ezomeprazol pharmacokinetics, duration of antisecretory effect, and reasons for their probable changes in duodenal ulcer
Serebrova, S.I.; Starodubtsev, A.K.; Pisarev, V.V.; Kondratenko, S.N.; Vasilenko, G.F.; Dobrovol'skiĭ, O.V.
Eksperimental'naia i Klinicheskaia Gastroenterologiia 4: 86-92
2009
ISSN/ISBN: 1682-8658 PMID: 19960999 Document Number: 630694
There were authentic distinctions between the groups of healthy volunteers and patients with a peptic ulcer disease in Cmax, Tmax, AUC(0-t), AUC(0-infinity), CIt, Vd of omeprazole and Cmax of esomeprazole (Nexium, AstraZeneca). When the pharmacokinetics of omeprazole and ezomeprazole were compared in both groups, there were authentic distinctions in Cmax, AU(0-t), AUC(0-infinity), CIt, T1/2. The patients who had taken omeprazole the time of hypoacide condition was much shorter than in other groups. Disintegration test modeling pHmax for pH oscillation with large amplitude, that is typical for ulcer disease, demonstrated a possibility of early partial release of omeprazole, its acid-depended degradation and reduction of its bioavailability.